Table 2 AUCs for predictive ability of CVD risk assessment tools for fatal, non-fatal and composite CVD events in phase I of the cohort based on gender.
Gender | Risk assessment tools | P-value | ||||
|---|---|---|---|---|---|---|
SCORE low European countries | SCORE high European countries | ACC/AHA tool | Framingham | SCORE2 for moderate, CVD risk populations*** | ||
AUC (95% CI) for fatal CVD events | ||||||
Men* | 0.8273 (0.7295–0.9304) | 0.8273 (0.7302–0.9244) | 0.9287 (0.8871–0.9703) | 0.9119 (0.8586–0.9652) | 0.8332 (0.7524–0.9139) | 0.0015 |
Women** | 0.8551 (0.7509–0.9593) | 0.8540 (0.7495–0.9585) | 0.8794 (0.7987–0.9601) | 0.8609 (0.7797–0.9421) | 0.8712 (0.7696–0.9728) | 0.1604 |
AUC (95% CI) for non-fatal CVD events | ||||||
Men* | 0.6297 (0.5536–0.7059) | 0.6279 (0.5514–0.7043) | 0.6370 (0.5642–0.7098) | 0.6279 (0.5527–0.7032) | 0.6351 (0.5624–0.7077) | 0.5699 |
Women** | 0.6933 (0.6002–0.7865) | 0.6940 (0.6017–0.7863) | 0.7553 (0.6766–0.8340) | 0.7319 (0.6572–0.8066) | 0.7318 (0.6549-8088) | 0.0084 |
AUC (95% CI) for composite (fatal and non-fatal) CVD events | ||||||
Men* | 0.6652 (0.5944–0.7360) | 0.6636 (0.5924–0.7348) | 0.6879 (0.6206–0.7552) | 0.6774 (0.6081–0.7466) | 0.6680 (0.6014–0.7345) | 0.2107 |
Women** | 0.7357 (0.6603–0.8110) | 0.7359 (0.6612–0.8106) | 0.7903 (0.7268–0.8538) | 0.7674 (0.7058–0.8290) | 0.7692 (0.7036–0.8348) | 0.0019 |